专利检索_ .丝氨酸内肽酶专利检索_ .丝氨酸内肽酶专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
61	ENZYME SYSTEM FOR EXTRACTION OF PROTEINS FROM DISTILLERS GRAINS	US14605931	2015-01-26	US20150208688A1	2015-07-30	Ian Mackay
An enzyme system for the extraction of proteins from distillers grains and roots. The enzyme system is a three component system containing a first component of protease enzyme and a buffer, a second component comprised of a deactivating agent, and a third component comprised of neutralizing agent.
62	Multiple Mutation Variants of Serine Protease	US14483375	2014-09-11	US20150072913A1	2015-03-12	Wolfgang Aehle; David A. Estell; Ronaldus W.J. Hommes; Brian E. Jones; Marc Kolkman; Chris Leeflang; Hiroshi Oh; Ayrookaran J. Poulose; Andrew Shaw; Wilhelmus A.H. Van der Kley; Leonardus P.M. Van Marrewijk
The present invention provides novel Micrococcineae spp serine proteases having multiple substitutions. In particular, the present invention provides serine proteases having multiple substitutions, DNA encoding these proteases, vectors comprising the DNA encoding the proteases, host cells transformed with the vector DNA, and enzymes produced by the host cells. The present invention also provides cleaning compositions (e.g., detergent compositions), animal feed compositions, and textile and leather processing compositions comprising these serine protease variants. In particularly preferred embodiments, the present invention provides mutant (i.e., variant) proteases derived from the wild-type proteases described herein. These variant proteases also find use in numerous applications.
63	METHOD FOR PRODUCING FATTY ACID ESTER	US14382688	2013-04-01	US20150056671A1	2015-02-26	Saki Hamada; Hiroyuki Konishi; Takaaki Watanabe
Provided is a method of producing a fatty acid ester in a high yield through a simple operation using Euglena as a material. The method of producing a fatty acid ester comprises the following steps (a) and (b): (a) adding 0.001 to 9.5 [PU/g-dry cell] of at least one kind of protease to Euglena to react the Euglena and the protease in an aqueous phase; and (b) performing phase separation and collection of a fatty acid ester from a reaction liquid of the step (a).
64	Sickled Erythrocytes and Progenitors Target Cytotoxics to Tumors	US14222292	2014-03-21	US20150037297A1	2015-02-05	David S Terman
The present invention provides therapeutic mammalian cells which synthesize and express SS hemoglobin and a tumoricidal transgene. They are produced by transduction of SS erythroid progenitors/erythroblasts using viral vectors comprising a tumoricidal transgene operatively linked to the coding region of SS β-globin promoter/enhancer. Such transduced SS erythroid cells differentiate into mature SSRBCs that exhibit sustained synthesis and expression of SS hemoglobin, a tumoricidal protein(s). Both mature and progenitor SS-cells carrying tumoricidal transgene(s) are capable of selectively localizing in tumor microenvironment, occluding tumor microvessels and inducing a tumoricidal response.
65	Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same	US14207143	2014-03-12	US20140363433A1	2014-12-11	W. Jason Cummings; Patrick Gray; Larry Tjoelker; Munehisa Yabuki
In one aspect, the invention provides a method of making a bioactive peptide-bearing antibody, or fragment thereof, comprising (a) engrafting the amino acid sequence of at least one bioactive peptide of interest into (i) at least one of CDR-H1, CDR-H2 or CDR-H3 of a heavy chain variable region comprising one or more chicken framework regions and/or (ii) at least one of CDR-L1, CDR-L2 or CDR-L3 of the light chain variable region comprising one or more chicken framework regions, and (b) determining whether the antibody has substantially the same biological activity as the bioactive peptide.
66	Multiple mutation variants of serine protease	US13888300	2013-05-06	US08865449B2	2014-10-21	Wolfgang Aehle; David A. Estell; Ronaldus W. J. Hommes; Brian E. Jones; Marc Kolkman; Chris Leeflang; Hiroshi Oh; Ayrookaran J. Poulose; Andrew Shaw; Wilhelmus A. H. Van der Kley; Leonardus P. M. Van Marrewijk
The present invention provides novel Micrococcineae spp serine proteases having multiple substitutions. In particular, the present invention provides serine proteases having multiple substitutions, DNA encoding these proteases, vectors comprising the DNA encoding the proteases, host cells transformed with the vector DNA, and enzymes produced by the host cells. The present invention also provides cleaning compositions (e.g., detergent compositions), animal feed compositions, and textile and leather processing compositions comprising these serine protease variants. In particularly preferred embodiments, the present invention provides mutant (i.e., variant) proteases derived from the wild-type proteases described herein. These variant proteases also find use in numerous applications.
67	Polypeptides Having Protease Activity	US14237189	2012-08-17	US20140295027A1	2014-10-02	Carsten Sjoeholm; Peter Rahbek Oestergaard; Tine Hoff; Katrine Pontoppidan; Robert Piotr Olinski
The present invention relates to isolated polypeptides having protease activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides in e.g. animal feed and detergents.
68	Polypeptides Having Protease Activity and Polynucleotides Encoding Same	US14125645	2012-06-22	US20140206594A1	2014-07-24	Martin Simon Borchert; Jeppe Wegener Tams
The present invention relates to isolated polypeptides having protease activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
69	COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE	US14007835	2012-03-28	US20140194489A1	2014-07-10	David Bumcrot; Brian Bettencourt; Ivanka Toudjarska
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.
70	Protease Enzyme and Uses Thereof	US13433984	2012-03-29	US20120252064A1	2012-10-04	Leena Valtakari; Kari Juntunen; Marja Paloheimo; Pentti Ojapalo
The present invention is related to a fungal serine protease enzyme, which said enzyme has serine protease activity and comprises an amino acid sequence of Malbranchea ALKO4122 mature protease as defined in SEQ ID NO:18 or an amino acid sequence having at least 66% identity to the amino acid sequence of SEQ ID NO:18. Also disclosed is an isolated nucleic acid molecule, comprising a polynucleotide sequence which encodes a fungal serine protease enzyme, nucleic acid sequences encoding said protease, a host cell and a process of producing a polypeptide having serine protease activity. Said protease is useful as an enzyme preparation applicable in detergent compositions and for treating fibers, wool, hair, leather, or silk, for treating food or feed, or for any applications involving modification, degradation or removal of proteinaceous material.
71	METHODS FOR IMPROVING GUT HEALTH	US13079541	2011-04-04	US20120225050A1	2012-09-06	Chris D. Knight; Julia J. Dibner; Fenglan Yan
The present invention provides methods for improving gut health. In particular, the invention provides methods for improving gut health by improving the digestibility of dietary proteins, decreasing the flow of protein to the lower gastrointestinal tract, and/or decreasing the levels of Clostridium bacteria the upper intestinal tract of a subject. The methods comprise administering to the subject a supplement consisting essentially of at least one protease.
72	REDUCED-PRESSURE TREATMENT SYSTEMS AND METHODS EMPLOYING DEBRIDEMENT MECHANISMS	US13462817	2012-05-03	US20120220924A1	2012-08-30	Charles Alan Seegert; Robert Peyton Wilkes
Reduced-pressure treatment systems and methods are disclosed that employ debridement mechanisms to remove unwanted tissue. In one instance, a reduced-pressure treatment system for treating a tissue site on a patient includes a manifold member for distributing reduced pressure to the tissue site, a support member for disposing proximate the tissue site and the manifold, and a debridement mechanism coupled to the support member. The debridement mechanism is for debriding the tissue site. The system further includes a sealing drape for placing over the tissue site and manifold member. The sealing drape is operable to form a fluid seal over the tissue site and manifold member. The system also includes a reduced-pressure subsystem for delivering a reduced pressure to the sealing drape. The system may further include a chemical-debridement subsystem. Other systems, manifolds, and methods are disclosed.
73	Multiple mutation variants of serine protease	US11809104	2007-05-31	US20080063774A1	2008-03-13	Wolfgang Aehle; David Estell; Ronaldus Hommes; Brian Jones; Marc Kolkman; Chris Leeflang; Hiroshi Oh; Ayrookaran Poulose; Andrew Shaw; Wilhelmus Van Der Kley; Leonardus Van Marrewijk
The present invention provides novel Micrococcineae spp serine proteases having multiple substitutions. In particular, the present invention provides serine proteases having multiple substitutions, DNA encoding these proteases, vectors comprising the DNA encoding the proteases, host cells transformed with the vector DNA, and enzymes produced by the host cells. The present invention also provides cleaning compositions (e.g., detergent compositions), animal feed compositions, and textile and leather processing compositions comprising these serine protease variants. In particularly preferred embodiments, the present invention provides mutant (i.e., variant) proteases derived from the wild-type proteases described herein. These variant proteases also find use in numerous applications.
74	遺伝的改変酵母細胞と血栓特異的ストレプトキナーゼ製造改良プロセス	JP2018521564	2016-10-26	JP2018531611A	2018-11-01	サーニギリシュ; ジョシキショールクマール
本明細書に開示されるものは、生物学的に活性な血栓特異的ストレプトキナーゼ(CSSK)タンパク質をメチル栄養性酵母で生成及び分泌する発現系である。酵母発現CSSKタンパク質は、改善されたプラスミノーゲン活性化及びフィブリン選択性を示す。更に開示されるものは、改変シグナル配列が付加されたCSSKをコードする機能的cDNA配列の少なくとも1つのコピーで形質転換されたメチル栄養性酵母である。前記改変シグナル配列は成熟かつ正確にプロセッシングされたCSSKの分泌をもたらす。
75	LPAの遺伝子発現の阻害のための組成物及び方法	JP2018516738	2016-09-30	JP2018529732A	2018-10-11	メルクイスト, ステイシー; カナー, スティーブン; ロゼマ, デイビッドビー.; ルイス, デイビッドエル.; アルメイダ, ローレンジェイ.; ウェイクフィールド, ダレンエイチ.; トルベツコイ, ウラジーミルエス.; ペイ, タオ; リ, ゼン; アルメイダ, アーロン
LPA(アポ(a))遺伝子の発現の阻害のためのRNA干渉(RNAi)剤及びRNAi剤コンジュゲートが記載される。1つまたは複数のLPA RNAi剤を随意で1つまたは複数の追加の治療剤と共に含む医薬組成物も記載される。記載されるLPA RNAi剤の肝細胞へのインビボでの送達は、LPA遺伝子発現の阻害ならびに心血管性疾患及び心血管関連疾患の治療を提供する。本明細書において記載されるRNAi剤は、LPA遺伝子を発現する細胞への送達に際して、RNA干渉(RNAi)の生物学的プロセスを介してLPAの発現をインビトロ及び/またはインビボで阻害またはノックダウンする。【選択図】なし
76	セリアックスプルー病を治療するための組成物および方法	JP2014525175	2012-08-10	JP6342802B2	2018-06-13	シーゲル、ジャスティン; ベイカー、デビッド; ゴードン、シドニーリンアナ; パルツ、イングリッドスワンソン; スタンレー、エリザベスジョイ; ウルフ、サラジェーン

77	ＴＭＰＲＳＳ６発現を調節するための化合物及び方法	JP2017546624	2016-04-04	JP2018511307A	2018-04-26	グオ,スーリン; アガジャン,マリアム; スウェイジ,エリック・イー
【要約書】修飾オリゴヌクレオチドを含む組成物及び化合物であって、TMPRSS6を調節し、かつそれを必要とする個体における鉄蓄積疾患、障害及び/または病態を調節する、修飾オリゴヌクレオチドを含む組成物及び化合物を開示する。個体おける赤血球増加症、ヘモクロマトーシス、またはβ‐サラセミア等の鉄蓄積疾患を、TMPRSS6を標的とするアンチセンス化合物を投与することで、治療、寛解、進行の遅延または予防することができる。【選択図】なし
78	ポルフィロモナス・ジンジバリス感染の予防、治療及び診断	JP2015130074	2015-06-29	JP6235533B2	2017-11-22	レイノルズエリックチャールズ; オブライエンシンプソンニールマーティン; スラケスキナーダ; クロスキースジェイ.

79	バチルス（Ｂａｃｉｌｌｕｓ）種のセリンプロテアーゼ	JP2017501136	2015-03-20	JP2017519515A	2017-07-20	コルクマン、マーク; ヘミングセン、アンジャ; メジルダル、リエ; ボット、リチャード; ベイブ、リリア
本開示は、バチルス(Bacillus)種からクローニングされたセリンプロテアーゼ、及びその変異体に関する。セリンプロテアーゼを含有している組成物は、布地及び硬質表面のクリーニング、並びに様々な工業用途に好適である。【選択図】図1
80	天然抗体に基づくＭＡｐ４４ポリペプチドおよび構築物ならびにそれらの使用	JP2016571256	2015-06-04	JP2017518318A	2017-07-06	ブイ．マイケルホラーズ，; ナーマルバンダ，; リュドミラクーリック，
本発明は、個体における炎症性疾患を処置するための送達方法および構築物を提供する。ターゲティング送達アプローチは、炎症部位に存在することが見出されたエピトープを認識する抗体を利用する。前記抗体を使用して、MAp44ポリペプチドまたはその断片を炎症部位に送達し、そこでそれが補体活性化のレクチン経路を阻害する。個体における補体媒介性疾患を処置する方法であって、構築物を含む有効量の組成物を該個体に投与することを含み、該構築物が、MAp44ポリペプチドまたはその断片を含む、方法。

1 2 3 4 5 6 7 8 9 10

该功能需要专业版企业版VIP权限，您可以：